FPH Limiteds Preliminary Final Report and Dividend/Distribution.

On 26 May 2023, Fisher & Paykel Healthcare Corporation Limited (ASX: FPH) reported a 6% decrease in total operating revenue for FY2023, amounting to AU$1.58 billion, or a 9% decline in constant currency compared to the previous year. Net profit after tax also experienced a significant decline of 34%, reaching AU$250.3 million, or a 39% decline in constant currency.

However, during the second half of the year, FPH saw positive growth with operating revenue increasing by 14% to AU$890.5 million, or 12% growth in constant currency, driven by strong performance in Hospital new applications consumables and OSA masks revenue. The company’s investment of AU$174.3 million in research and development shows its dedication to new products and growth. The board approved a final dividend of 23.0 cents/share for the second half, totaling 40.5 cents/share for FY2023, a 3% increase from last year.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com